JP2008504274A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008504274A5 JP2008504274A5 JP2007518256A JP2007518256A JP2008504274A5 JP 2008504274 A5 JP2008504274 A5 JP 2008504274A5 JP 2007518256 A JP2007518256 A JP 2007518256A JP 2007518256 A JP2007518256 A JP 2007518256A JP 2008504274 A5 JP2008504274 A5 JP 2008504274A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- cycloalkyl
- heteroaryl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000753 cycloalkyl group Chemical group 0.000 claims 133
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 128
- 125000003118 aryl group Chemical group 0.000 claims 106
- 125000001072 heteroaryl group Chemical group 0.000 claims 92
- 125000000217 alkyl group Chemical group 0.000 claims 91
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 74
- 125000003710 aryl alkyl group Chemical group 0.000 claims 67
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 67
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 45
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 45
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 44
- 125000005843 halogen group Chemical group 0.000 claims 44
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 30
- 229910052799 carbon Inorganic materials 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 125000004432 carbon atom Chemical group C* 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 18
- 125000005466 alkylenyl group Chemical group 0.000 claims 18
- 229910052760 oxygen Inorganic materials 0.000 claims 18
- 229910052717 sulfur Inorganic materials 0.000 claims 18
- 125000004429 atom Chemical group 0.000 claims 16
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 12
- 125000003282 alkyl amino group Chemical group 0.000 claims 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 12
- 125000004663 dialkyl amino group Chemical group 0.000 claims 12
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 11
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 10
- -1 C (O) OR 16 Chemical group 0.000 claims 8
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 8
- 125000002619 bicyclic group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- VLSXXHVAWRTHMV-GJZGRUSLSA-N (3s)-1-[(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidine-3-carbonyl]piperidine-3-carboxylic acid Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2C[C@H](CCC2)C(O)=O)CCC1 VLSXXHVAWRTHMV-GJZGRUSLSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 1
- AXFFBWOXZAVNPE-UHFFFAOYSA-N 1'-[1-(benzenesulfonyl)piperidine-3-carbonyl]spiro[2-benzofuran-3,3'-pyrrolidine]-1-one Chemical compound C1CC2(C3=CC=CC=C3C(=O)O2)CN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 AXFFBWOXZAVNPE-UHFFFAOYSA-N 0.000 claims 1
- YVYUWSZAJHKIGM-UHFFFAOYSA-N 1,3,3a,4,5,9b-hexahydrobenzo[e]isoindol-2-yl-[1-(benzenesulfonyl)piperidin-3-yl]methanone Chemical compound C1C2CCC3=CC=CC=C3C2CN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 YVYUWSZAJHKIGM-UHFFFAOYSA-N 0.000 claims 1
- 125000004562 2,3-dihydroindol-1-yl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- JUPAKBAVGWUQPS-GNZRSQJKSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-quinolin-1-yl-[(3s)-1-(3-bromophenyl)sulfonylpiperidin-3-yl]methanone Chemical compound BrC1=CC=CC(S(=O)(=O)N2C[C@H](CCC2)C(=O)N2C3CCCCC3CCC2)=C1 JUPAKBAVGWUQPS-GNZRSQJKSA-N 0.000 claims 1
- AHXMVKYKVRBJSO-FDYSRKEFSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-quinolin-1-yl-[(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidin-3-yl]methanone Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2C3CCCCC3CCC2)CCC1 AHXMVKYKVRBJSO-FDYSRKEFSA-N 0.000 claims 1
- PXUURYWUNSXDKI-QGZVFWFLSA-N 3,4-dihydro-2h-quinolin-1-yl-[(3r)-1-(2-nitrophenyl)sulfonylpiperidin-3-yl]methanone Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)N1C[C@H](C(=O)N2C3=CC=CC=C3CCC2)CCC1 PXUURYWUNSXDKI-QGZVFWFLSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- DQICGTZZGCTBOK-KSZLIROESA-N [(3ar,7as)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-[(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidin-3-yl]methanone Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2C[C@@H]3CCCC[C@@H]3C2)CCC1 DQICGTZZGCTBOK-KSZLIROESA-N 0.000 claims 1
- JWZFTJNOTOTYCO-QRWMCTBCSA-N [(3r)-1-(2-nitrophenyl)sulfonylpiperidin-3-yl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)N1C[C@H](C(=O)N2CC(CC2)C=2C=NC=CC=2)CCC1 JWZFTJNOTOTYCO-QRWMCTBCSA-N 0.000 claims 1
- ZKOOSEKUIZQMKP-GOSISDBHSA-N [(3r)-1-(benzenesulfonyl)piperidin-3-yl]-(3,4-dihydro-2h-quinolin-1-yl)methanone Chemical compound C([C@H](C1)C(=O)N2C3=CC=CC=C3CCC2)CCN1S(=O)(=O)C1=CC=CC=C1 ZKOOSEKUIZQMKP-GOSISDBHSA-N 0.000 claims 1
- ZKXHVQWPDAHNCF-MUMRKEEXSA-N [(3r)-1-(benzenesulfonyl)piperidin-3-yl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound C([C@H](C1)C(=O)N2CC(CC2)C=2C=NC=CC=2)CCN1S(=O)(=O)C1=CC=CC=C1 ZKXHVQWPDAHNCF-MUMRKEEXSA-N 0.000 claims 1
- GTLATAUWZQTMEA-ZVAWYAOSSA-N [(3s)-1-(2-chlorophenyl)sulfonylpiperidin-3-yl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound ClC1=CC=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2CC(CC2)C=2C=NC=CC=2)CCC1 GTLATAUWZQTMEA-ZVAWYAOSSA-N 0.000 claims 1
- XOZBTMPFBWBSMA-GGYWPGCISA-N [(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidin-3-yl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2CC(CC2)C=2C=NC=CC=2)CCC1 XOZBTMPFBWBSMA-GGYWPGCISA-N 0.000 claims 1
- XOZBTMPFBWBSMA-OALUTQOASA-N [(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidin-3-yl]-[(3r)-3-pyridin-3-ylpyrrolidin-1-yl]methanone Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2C[C@H](CC2)C=2C=NC=CC=2)CCC1 XOZBTMPFBWBSMA-OALUTQOASA-N 0.000 claims 1
- XOZBTMPFBWBSMA-MOPGFXCFSA-N [(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidin-3-yl]-[(3s)-3-pyridin-3-ylpyrrolidin-1-yl]methanone Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2C[C@@H](CC2)C=2C=NC=CC=2)CCC1 XOZBTMPFBWBSMA-MOPGFXCFSA-N 0.000 claims 1
- QGYHFRPWONVZNE-NRFANRHFSA-N [(3s)-1-(benzenesulfonyl)piperidin-3-yl]-(4-phenylpiperidin-1-yl)methanone Chemical compound C([C@@H](C1)C(=O)N2CCC(CC2)C=2C=CC=CC=2)CCN1S(=O)(=O)C1=CC=CC=C1 QGYHFRPWONVZNE-NRFANRHFSA-N 0.000 claims 1
- VSXDUDCUQBOPRH-ZACQAIPSSA-N [(4ar,8as)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-[(3s)-1-(2,3-dichlorophenyl)sulfonylpiperidin-3-yl]methanone Chemical compound ClC1=CC=CC(S(=O)(=O)N2C[C@H](CCC2)C(=O)N2C[C@H]3CCCC[C@@H]3CC2)=C1Cl VSXDUDCUQBOPRH-ZACQAIPSSA-N 0.000 claims 1
- KCAFDATZQMJKNE-QRVBRYPASA-N [(4ar,8as)-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl]-[(3s)-1-(3-chloro-2-methylphenyl)sulfonylpiperidin-3-yl]methanone Chemical compound CC1=C(Cl)C=CC=C1S(=O)(=O)N1C[C@@H](C(=O)N2C[C@H]3CCCC[C@@H]3CC2)CCC1 KCAFDATZQMJKNE-QRVBRYPASA-N 0.000 claims 1
- JWZFTJNOTOTYCO-UHFFFAOYSA-N [1-(2-nitrophenyl)sulfonylpiperidin-3-yl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound [O-][N+](=O)C1=CC=CC=C1S(=O)(=O)N1CC(C(=O)N2CC(CC2)C=2C=NC=CC=2)CCC1 JWZFTJNOTOTYCO-UHFFFAOYSA-N 0.000 claims 1
- NKLSJXBJUMLONQ-UHFFFAOYSA-N [1-(benzenesulfonyl)piperidin-3-yl]-(3-methyl-4-phenylpiperazin-1-yl)methanone Chemical compound CC1CN(C(=O)C2CN(CCC2)S(=O)(=O)C=2C=CC=CC=2)CCN1C1=CC=CC=C1 NKLSJXBJUMLONQ-UHFFFAOYSA-N 0.000 claims 1
- VKDKBCGFNJUVLV-UHFFFAOYSA-N [1-(benzenesulfonyl)piperidin-3-yl]-(3-phenylpiperidin-1-yl)methanone Chemical compound C1CCC(C=2C=CC=CC=2)CN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 VKDKBCGFNJUVLV-UHFFFAOYSA-N 0.000 claims 1
- ZKXHVQWPDAHNCF-UHFFFAOYSA-N [1-(benzenesulfonyl)piperidin-3-yl]-(3-pyridin-3-ylpyrrolidin-1-yl)methanone Chemical compound C1CC(C=2C=NC=CC=2)CN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 ZKXHVQWPDAHNCF-UHFFFAOYSA-N 0.000 claims 1
- QGYHFRPWONVZNE-UHFFFAOYSA-N [1-(benzenesulfonyl)piperidin-3-yl]-(4-phenylpiperidin-1-yl)methanone Chemical compound C1CC(C=2C=CC=CC=2)CCN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 QGYHFRPWONVZNE-UHFFFAOYSA-N 0.000 claims 1
- MWUDAGTUMYLQHD-UHFFFAOYSA-N [1-(benzenesulfonyl)piperidin-3-yl]-spiro[1,3-dihydroindene-2,4'-piperidine]-1'-ylmethanone Chemical compound C1CC2(CC3=CC=CC=C3C2)CCN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 MWUDAGTUMYLQHD-UHFFFAOYSA-N 0.000 claims 1
- GPHZODVMJDGJKT-UHFFFAOYSA-N [1-(benzenesulfonyl)piperidin-3-yl]-spiro[1h-2-benzofuran-3,4'-piperidine]-1'-ylmethanone Chemical compound C1CC2(C3=CC=CC=C3CO2)CCN1C(=O)C(C1)CCCN1S(=O)(=O)C1=CC=CC=C1 GPHZODVMJDGJKT-UHFFFAOYSA-N 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 229960002478 aldosterone Drugs 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 CN1CCC(*)CC1 Chemical compound CN1CCC(*)CC1 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58247804P | 2004-06-24 | 2004-06-24 | |
| PCT/US2005/022170 WO2006012173A1 (en) | 2004-06-24 | 2005-06-23 | Amido compounds and their use as pharmaceuticals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008504274A JP2008504274A (ja) | 2008-02-14 |
| JP2008504274A5 true JP2008504274A5 (OSRAM) | 2008-08-07 |
Family
ID=35786518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007518256A Withdrawn JP2008504274A (ja) | 2004-06-24 | 2005-06-23 | アミド化合物およびその医薬としての使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050288317A1 (OSRAM) |
| EP (1) | EP1758882A4 (OSRAM) |
| JP (1) | JP2008504274A (OSRAM) |
| CN (1) | CN101001850A (OSRAM) |
| AU (1) | AU2005267331A1 (OSRAM) |
| BR (1) | BRPI0512630A (OSRAM) |
| CA (1) | CA2569507A1 (OSRAM) |
| MX (1) | MXPA06014573A (OSRAM) |
| WO (1) | WO2006012173A1 (OSRAM) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| US20050288338A1 (en) * | 2004-06-24 | 2005-12-29 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
| CA2589565A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| JP2008504280A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | ２−メチルプロパンアミドおよびその医薬としての使用 |
| JP2008504278A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
| US8071624B2 (en) * | 2004-06-24 | 2011-12-06 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| WO2006020598A2 (en) * | 2004-08-10 | 2006-02-23 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US8110581B2 (en) | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| CA2585797C (en) * | 2004-11-10 | 2015-01-06 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| CN101103016A (zh) * | 2004-11-18 | 2008-01-09 | 因塞特公司 | 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法 |
| US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| AU2006203918B2 (en) | 2005-01-05 | 2011-05-19 | Abbvie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| CA2594098C (en) | 2005-01-05 | 2014-04-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| BRPI0609062A2 (pt) * | 2005-03-03 | 2010-02-17 | F. Hofmann-La Roche Ag | composição farmacêutica, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróide-11ß e utilização dos compostos |
| JP5140577B2 (ja) * | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
| AR053710A1 (es) | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| EP2527337A1 (en) * | 2005-04-14 | 2012-11-28 | Bristol-Myers Squibb Company | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| CA2621255A1 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| WO2007067504A2 (en) * | 2005-12-05 | 2007-06-14 | Incyte Corporation | Lactam compounds and methods of using the same |
| WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| TW200804341A (en) * | 2006-01-31 | 2008-01-16 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| EP1981848A2 (en) | 2006-02-07 | 2008-10-22 | Wyeth | 11-beta hsd1 inhibitors |
| US20070213311A1 (en) * | 2006-03-02 | 2007-09-13 | Yun-Long Li | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| EP2013163A1 (en) * | 2006-05-01 | 2009-01-14 | Incyte Corporation | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP2018378A2 (en) * | 2006-05-17 | 2009-01-28 | Incyte Corporation | Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same |
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| CN103271906A (zh) | 2006-10-12 | 2013-09-04 | 泽农医药公司 | 螺-吲哚酮化合物作为治疗剂的用途 |
| CN101605456A (zh) * | 2006-12-20 | 2009-12-16 | 詹森药业有限公司 | 用甲硅烷基试剂由哌啶酮合成不饱和哌啶 |
| DK2142533T3 (da) * | 2007-03-30 | 2011-12-12 | Hoffmann La Roche | Imidazolidinonderivater |
| CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
| CA2695088C (en) | 2007-08-13 | 2013-03-12 | F. Hoffmann-La Roche Ag | Novel piperazine amide derivatives |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| WO2009100994A1 (en) * | 2008-02-12 | 2009-08-20 | F. Hoffmann-La Roche Ag | Piperidine sulfonamide derivatives |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| CN103664973B (zh) | 2008-10-17 | 2017-04-19 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| US8101647B2 (en) | 2008-10-17 | 2012-01-24 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| BR112012003973A2 (pt) | 2009-08-26 | 2015-09-08 | Sanofi Sa | hidratos de fluoroglicosídeo heteroaromático cristalinos, produtos farmacêuticos compreendendo estes compostos e seu uso |
| US8445696B2 (en) | 2009-10-14 | 2013-05-21 | Xenon Pharmaceuticals Inc. | Synthetic methods for spiro-oxindole compounds |
| BR112012021086A2 (pt) | 2010-02-26 | 2016-05-17 | Xenon Pharmaceuticals Inc | composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8809325B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120050A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| KR102351054B1 (ko) * | 2019-11-11 | 2022-01-14 | 엠비디 주식회사 | 신규한 퀴놀린 화합물 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4439606A (en) * | 1982-05-06 | 1984-03-27 | American Cyanamid Company | Antiatherosclerotic 1-piperazinecarbonyl compounds |
| DE4234295A1 (de) * | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| FR2705343B1 (fr) * | 1993-05-17 | 1995-07-21 | Fournier Ind & Sante | Dérivés de beta,beta-diméthyl-4-pipéridineéthanamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| FR2724656B1 (fr) * | 1994-09-15 | 1996-12-13 | Adir | Nouveaux derives du benzopyranne, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| IL115420A0 (en) * | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
| FR2736053B1 (fr) * | 1995-06-28 | 1997-09-19 | Sanofi Sa | Nouvelles 1-phenylalkyl-1,2,3,6-tetrahydropyridines |
| US6087368A (en) * | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
| US7294637B2 (en) * | 2000-09-11 | 2007-11-13 | Sepracor, Inc. | Method of treating addiction or dependence using a ligand for a monamine receptor or transporter |
| NZ528450A (en) * | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
| WO2003000657A1 (en) * | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| US6547958B1 (en) * | 2001-07-13 | 2003-04-15 | Chevron U.S.A. Inc. | Hydrocarbon conversion using zeolite SSZ-59 |
| US6818772B2 (en) * | 2002-02-22 | 2004-11-16 | Abbott Laboratories | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| GB0213715D0 (en) * | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
| US20060019977A1 (en) * | 2002-10-18 | 2006-01-26 | Ono Pharmaceutical Co., Ltd. | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient |
| DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
| TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| US20050288338A1 (en) * | 2004-06-24 | 2005-12-29 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
| JP2008504278A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | アミド化合物およびその医薬としての使用 |
| CA2589565A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US8071624B2 (en) * | 2004-06-24 | 2011-12-06 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| JP2008504280A (ja) * | 2004-06-24 | 2008-02-14 | インサイト・コーポレイション | ２−メチルプロパンアミドおよびその医薬としての使用 |
| WO2006020598A2 (en) * | 2004-08-10 | 2006-02-23 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| CA2585797C (en) * | 2004-11-10 | 2015-01-06 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| CN101103016A (zh) * | 2004-11-18 | 2008-01-09 | 因塞特公司 | 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法 |
| AU2006203918B2 (en) * | 2005-01-05 | 2011-05-19 | Abbvie Inc. | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| BRPI0609062A2 (pt) * | 2005-03-03 | 2010-02-17 | F. Hofmann-La Roche Ag | composição farmacêutica, compostos, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por inibidores de deidrogenase de hidroxiesteróide-11ß e utilização dos compostos |
| CA2621255A1 (en) * | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| WO2007067504A2 (en) * | 2005-12-05 | 2007-06-14 | Incyte Corporation | Lactam compounds and methods of using the same |
| WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| TW200804341A (en) * | 2006-01-31 | 2008-01-16 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| US20070213311A1 (en) * | 2006-03-02 | 2007-09-13 | Yun-Long Li | Modulators of 11-beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| EP2013163A1 (en) * | 2006-05-01 | 2009-01-14 | Incyte Corporation | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
| EP2018378A2 (en) * | 2006-05-17 | 2009-01-28 | Incyte Corporation | Heterocyclic inhibitors of 11-b hydroxyl steroid dehydrogenase type i and methods of using the same |
-
2005
- 2005-06-23 US US11/159,863 patent/US20050288317A1/en not_active Abandoned
- 2005-06-23 WO PCT/US2005/022170 patent/WO2006012173A1/en not_active Ceased
- 2005-06-23 BR BRPI0512630-4A patent/BRPI0512630A/pt not_active IP Right Cessation
- 2005-06-23 AU AU2005267331A patent/AU2005267331A1/en not_active Abandoned
- 2005-06-23 CN CNA2005800205246A patent/CN101001850A/zh active Pending
- 2005-06-23 JP JP2007518256A patent/JP2008504274A/ja not_active Withdrawn
- 2005-06-23 EP EP05762850A patent/EP1758882A4/en not_active Withdrawn
- 2005-06-23 MX MXPA06014573A patent/MXPA06014573A/es not_active Application Discontinuation
- 2005-06-23 CA CA002569507A patent/CA2569507A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008504274A5 (OSRAM) | ||
| JP2008504279A5 (OSRAM) | ||
| RU2497813C2 (ru) | 4-(4-циано-2-тиоарил)-дигидропиримидиноны и их применение | |
| JP2008504278A5 (OSRAM) | ||
| DK1756063T3 (en) | Amido compounds and their use as pharmaceuticals | |
| US6265408B1 (en) | Sulphonamide derivatives and their use in the treatment of CNS disorders | |
| RU2005114489A (ru) | N-акрил-4-метиленамино-3-гидрокси-2-пиридоны в качестве противомикробных препаратов | |
| CA2569507A1 (en) | Amido compounds and their use as pharmaceuticals | |
| RU2395507C2 (ru) | Пиримидиновые производные | |
| RU2005102004A (ru) | Замещенные хинолины как антагонисты рецептора ccr5 | |
| JP2008509910A (ja) | アミド化合物およびその医薬としての使用 | |
| CA2569611A1 (en) | Indole derivatives as histamine receptor antagonists | |
| EP1758582A1 (en) | Amido compounds and their use as pharmaceuticals | |
| RU2005134006A (ru) | Производные 4-(4-{гетероциклилалкокси}фенил0-1-(гетероциклилкарбонил)пиперидина и родственные соединения как антагонисты гистамина н3 для лечения неврологических заболеваний, таких как болезнь альцгеймера | |
| JP2012510502A5 (OSRAM) | ||
| JP2008504279A (ja) | アミド化合物およびその医薬としての使用 | |
| RU2006100190A (ru) | Производные хинолиламида в качестве антагонистов ccr-5 | |
| AR076375A1 (es) | Piperazinil azetidinil amidas heteroaromaticas y aromaticas como inhibidores de lipasas de monoacilglicerol. | |
| AU2008258665B2 (en) | Prolinamide derivatives as NK3 antagonists | |
| RU2010108687A (ru) | Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3 | |
| CA2566526A1 (en) | Naphthaline derivatives useful as histamine-3-receptor ligands | |
| RU2009138219A (ru) | Новые бензамидные производные и способ их получения | |
| JP5892550B2 (ja) | 縮合イミダゾール誘導体 | |
| JP2007532596A5 (OSRAM) | ||
| RU2401267C2 (ru) | Замещенные производные бензохинолизина |